logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Terns Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 13


Forward Citations = 14

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal F Anthony Romero (11 out of 42 patents)

silverMedal Christopher T Jones (9 out of 9 patents)

bronzeMedal Corey Reeves (8 out of 8 patents)

4.  Martijn Fenaux (7 out of 18 patents)

5.  Randall Halcomb (4 out of 46 patents)

6.  Yingzi Xu (4 out of 8 patents)

7.  Thorsten A Kirschberg (4 out of 44 patents)

8.  Gary W Luehr (3 out of 3 patents)

9.  Kevin P Quinn (2 out of 2 patents)

10.  Olivia D Teal (1 out of 1 patent)

11.  Jeffrey R Jasper (1 out of 1 patent)

12.  Shanghai Yu (0 patent)

13.  Ben Li (0 patent)

14.  Ben Li (0 patent)

15.  Shanghai Yu (0 patent)


13 patents:

1. 12528791 - Thyroid hormone receptor beta agonist compounds (2026-01-20),
2. 12522596 - Compounds as GLP-1R agonists (2026-01-13),
3. 12486261 - Compounds as GLP-1R agonists (2025-12-02),
4. 12485118 - Combinations of GLP-1R and THRβ agonists and methods of use thereof (2025-12-02),
5. 12454524 - (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias (2025-10-28),
6. 12410163 - Compounds as GLP-IR agonists (2025-09-09),
7. 12398127 - Thyroid hormone receptor beta agonist compounds (2025-08-26),
8. 12378239 - Compounds as GLP-1R agonists (2025-08-05),
9. 12378238 - Compounds as GLP-1R agonists (2025-08-05),
10. 12378237 - Compounds as GLP-1R agonists (2025-08-05),
11. 12378236 - Compounds as GLP-1R agonists (2025-08-05),
12. 12240835 - Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity (2025-03-04),
13. 12024507 - Compounds as GLP-1R agonists (2024-07-02),
Company Overview
Terns Pharmaceuticals, Inc. is a biotechnology company based in Foster City, California, focused on developing innovative therapies for liver diseases. The company specializes in advancing novel drug candidates that target specific pathways involved in liver health and metabolic disorders. Terns leverages cutting-edge research and technology to address unmet medical needs, aiming to improve patient outcomes through its commitment to scientific excellence and rigorous clinical development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#36 in Foster City, CA

#5,664 in California

#23,863 in US

#45,104 in the World

Foster City, CA (US)
Foster City, CA, United States of America

Terns Pharmaceuticals, Inc.

Forward Citations = 14

15 inventors:

goldMedal F Anthony Romero (11 out of 42 patents)

silverMedal Christopher T Jones (9 out of 9 patents)

bronzeMedal Corey Reeves (8 out of 8 patents)

4.  Martijn Fenaux (7 out of 18 patents)

5.  Randall Halcomb (4 out of 46 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Terns Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/terns-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…